Wealthfront Advisers LLC Makes New $150,000 Investment in Novavax, Inc. (NASDAQ:NVAX)

Wealthfront Advisers LLC acquired a new position in shares of Novavax, Inc. (NASDAQ:NVAX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 18,637 shares of the biopharmaceutical company’s stock, valued at approximately $150,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Spire Wealth Management bought a new stake in Novavax during the 4th quarter worth about $29,000. KBC Group NV raised its holdings in Novavax by 97.0% during the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 3,917 shares during the last quarter. TigerOak Management L.L.C. bought a new stake in shares of Novavax in the 4th quarter valued at about $86,000. AlphaQuest LLC increased its stake in shares of Novavax by 290.1% in the 4th quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 7,940 shares during the last quarter. Finally, Entropy Technologies LP bought a new stake in shares of Novavax in the 3rd quarter valued at about $158,000. 53.04% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Novavax news, Director James F. Young sold 5,400 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the transaction, the director now owns 51,760 shares of the company’s stock, valued at $414,080. This represents a 9.45 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.00% of the company’s stock.

Novavax Stock Performance

Shares of NVAX opened at $8.38 on Tuesday. The stock has a 50 day simple moving average of $8.41 and a 200 day simple moving average of $9.62. Novavax, Inc. has a 52-week low of $3.81 and a 52-week high of $23.86. The firm has a market capitalization of $1.35 billion, a PE ratio of -3.71, a P/E/G ratio of 2.85 and a beta of 2.92.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.24. The business had revenue of $88.31 million during the quarter, compared to analyst estimates of $85.48 million. During the same quarter in the prior year, the firm posted ($1.44) earnings per share. Equities research analysts predict that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NVAX has been the subject of a number of recent analyst reports. BTIG Research initiated coverage on Novavax in a research note on Friday, February 28th. They issued a “buy” rating and a $19.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price target on shares of Novavax in a research note on Tuesday, December 10th. Finally, TD Cowen raised Novavax to a “hold” rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $18.00.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.